177
Participants
Start Date
June 12, 2020
Primary Completion Date
November 17, 2020
Study Completion Date
November 17, 2020
Acalabrutinib
Acalabrutinib- administered orally
Research Site, Ciudad de Buenos Aires
Research Site, Johannesburg
Research Site, Johannesburg
Research Site, George
Research Site, Cape Town
Research Site, D.F
Research Site, Lima
Research Site, Milan
Research Site, Bakırköy
Research Site, Istanbul
Research Site, Umraniye
Research Site, Cologne
Research Site, Frankfurt
Research Site, Monterrey
Research Site, Gauting
Research Site, Villejuif
Research Site, New Delhi
Research Site, Moscow
Research Site, Moscow
Research Site, Moscow
Research Site, Moscow
Research Site, Murmansk
Research Site, Bangalore
Research Site, Curicó
Research Site, Talca
Research Site, Santiago
Research Site, Ciudad de Buenos Aires
Research Site, Monte Grande
Research Site, Ramos Mejía
Research Site, Botucatu
Research Site, Brasillia
Research Site, Florianópolis
Research Site, Porto Alegre
Research Site, Porto Alegre
Research Site, Ribeirão Preto
Research Site, Salvador
Research Site, São Bernardo do Campo
Research Site, São Paulo
Research Site, São Paulo
Research Site, São Paulo
Research Site, Roma
Research Site, Shinjuku-ku
Research Site, México
Research Site, Lima
Research Site, Lima
Research Site, Warsaw
Research Site, Warsaw
Research Site, Pretoria
Research Site, Ankara
Research Site, Istanbul
Lead Sponsor
Collaborators (1)
Acerta Pharma BV
INDUSTRY
AstraZeneca
INDUSTRY